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Impaired Nuclear Export of 
Polyglutamine-Expanded 
Androgen Receptor in Spinal and 
Bulbar Muscular Atrophy
Frederick J. Arnold, Anna Pluciennik & Diane E. Merry
Spinal and bulbar muscular atrophy (SBMA) is a neuromuscular disease caused by polyglutamine 
(polyQ) expansion in the androgen receptor (AR). Prior studies have highlighted the importance of 
AR nuclear localization in SBMA pathogenesis; therefore, in this study, we sought to determine the 
role of AR nuclear export in the pathological manifestations of SBMA. We demonstrate here that the 
nuclear export of polyQ-expanded AR is impaired, even prior to the formation of intranuclear inclusions 
of aggregated AR. Additionally, we find that promoting AR export with an exogenous nuclear export 
signal substantially reduces its aggregation and blocks hormone-induced toxicity. Moreover, we show 
that these protective effects are conferred by destabilization of the mutant protein due to an increase 
in proteasomal degradation of the cytoplasmic AR. Despite a growing body of evidence that global 
disruption of nucleo/cytoplasmic transport occurs in ALS and HD, our data suggest that no such global 
disruption occurs in models of SBMA; rather, AR-specific mechanisms, including reduced phosphorylation 
at Serine 650, are likely responsible for the impaired nuclear export of polyQ-expanded AR.
Spinal and bulbar muscular atrophy (SBMA) is an X-linked neuromuscular disease caused by a 
polyglutamine-encoding CAG trinucleotide repeat expansion in the first exon of the androgen receptor gene1. 
SBMA affects approximately 1 in 40,000 males2, with onset of neurologic symptoms typically occurring between 
30 and 50 years of age3,4. As in other CAG trinucleotide repeat disorders, such as Huntington’s Disease (HD), 
longer CAG repeat tracts are associated with earlier disease onset3,5,6.
SBMA is characterized by progressive degeneration of lower motor neurons in the brain stem and spinal cord, 
which, along with a primary myopathy7, causes weakness and cramping of the muscles, dysphagia, dysarthria, 
and immobility2,3,8–11. Additionally, progressive loss of the bulbar musculature predisposes patients to potentially 
fatal aspiration-induced pneumonia. While SBMA patients show signs of androgen insensitivity, including gyne-
comastia and reduced fertility, the neurologic symptoms of SBMA are not caused by a loss of AR function, as 
neuromuscular symptoms are not observed in patients with complete androgen insensitivity syndrome12. Rather, 
SBMA is caused by a toxic property of polyQ-expanded AR, as further evidenced by the fact that expression of 
polyQ-expanded AR in the presence of ligand is sufficient to cause neuromuscular symptoms in mouse mod-
els13–16 and toxicity in cultured cells17. Moreover, while evidence from a Drosophila model of SBMA suggests that 
SBMA arises from a gain of native transcriptional activities18, findings from a knock-in mouse model of SBMA 
suggest that enhancing AR transcriptional activity can be protective19.
The AR is a steroid hormone receptor that resides in the cytoplasm, in the absence of ligand, in an inac-
tive aporeceptor complex that contains chaperones (Hsc70, Hsp40, Hsp90, HIP, HOP), p23, and immunophi-
lins (Cyp40, FKBP51, FKBP52)20,21. Upon binding of testosterone or 5α-dihydrotestosterone (DHT), the AR 
undergoes a conformational change, inducing its nuclear localization and transcriptional regulation of tar-
get genes. There is evidence that the AR is exported from the nucleus and degraded in the cytoplasm by the 
ubiquitin-proteasome system22–26.
In contrast with other aspects of AR metabolism, little is known about the mechanism of AR nuclear export. 
Mutagenesis experiments identified a 75-amino acid region (residues 743–817) in the AR ligand binding domain 
(LBD) that is both necessary and sufficient for AR nuclear export in a PC3 prostate cancer cell model27. The 
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putative nuclear export signal (NES) contained within this region is Leptomycin B-insensitive, suggesting that 
this regulatory motif is not a candidate for chromosomal maintenance 1 (CRM1) – mediated nuclear export upon 
hormone withdrawal23,27,28. However, a putative CRM1 binding site was identified near the C-terminus of the AR, 
and the rapid nuclear export of AR that occurs upon inhibition of GSK-3β in prostate cancer cells is blocked by 
Leptomycin B29,30. Thus, while AR undergoes slow, Leptomycin B-insensitive export upon hormone withdrawal, 
it may undergo rapid, CRM1-mediated nuclear export depending on the physiological conditions of the cell29. 
Interestingly, a similar phenomenon has been observed in the nuclear export of the glucocorticoid receptor (GR), 
a member of the nuclear receptor superfamily with a high degree of homology to the AR. While GR export 
induced by ligand withdrawal is slow and Leptomycin B-insensitive, GR undergoes rapid, Leptomycin-B sensitive 
nuclear export regulated by c-JUN N-terminal kinase (JNK) upon UV exposure31.
In addition to the NES identified in the AR LBD, residues in both the DNA-binding domain (DBD) and the 
hinge region also appear to regulate AR nuclear export. A double mutation in the DBD (F582, 583A) is sufficient 
to block nuclear export; however, DNA binding itself is not required for AR nuclear export, as the DNA-binding 
mutant V581F does not affect export32,33. Additionally, phosphorylation of the AR at serine 650 has been shown 
to regulate nuclear export of the AR34,35. In COS-7 and LNCaP cells, phosphorylation of S650 is mediated by 
the MAPK kinase 4/JNK and MAPK kinase 6/p38 stress kinase signaling pathways. Inhibition of JNK and p38 
reduced the nuclear export of wildtype AR in COS-7 cells to an equivalent extent as a phospho-null (S650A) 
mutation but had no effect on AR with a phospho-mimic (S650D) mutation34. Consistent with these findings, 
knockdown of MAP3k11, an upstream regulator of JNK activity, decreased S650 phosphorylation in LNCaP and 
C2-4B cells36. Additionally, inhibition of protein phosphatase 1 alpha (PP1α) by tautomycin led to an increase 
in S650 phosphorylation and a decrease in AR nuclear accumulation in LNCaP cells35. Notably, increasing AR 
nuclear export was associated with a decrease in its transcriptional activity, while blocking export increased AR 
transcriptional activity25,32,34,35.
Nuclear accumulation and aggregation of polyQ disease proteins is a common pathological feature of all nine 
CAG trinucleotide repeat disorders, highlighting its importance for further study37. While the extent to which 
toxicity in each of these diseases is mediated by nuclear versus cytoplasmic aggregation is not fully understood, 
targeting polyQ proteins to the nucleus or cytoplasm can modulate aggregation and/or toxicity in several cell and 
animal models of polyQ disease17,18,38–42. In some polyQ diseases, there is already evidence for defective nuclear 
export of the polyQ disease protein. For example, polyQ-expanded N-terminal huntingtin fragments exhibited 
a reduced interaction with the nuclear pore protein translocated promoter region (Tpr), increasing their nuclear 
accumulation43. Additionally, nuclear export of both mutant ataxin-3 and mutant ataxin-7 was reduced compared 
with the respective wildtype proteins39,44, while nuclear export of mutant ataxin-1 was completely blocked45. Thus, 
nuclear localization appears to play a key role in the pathogenesis of polyQ disease, with evidence for the thera-
peutic benefit of decreasing nuclear accumulation of some polyQ disease proteins.
In cell and animal models of SBMA, both the presence of hormone13,14,16,46 and the nuclear localization17,18,46 
of mutant AR are necessary for toxicity and neuromuscular pathology, with the formation of intranuclear inclu-
sions of aggregated AR in neuronal and non-neuronal tissues a hallmark of the disease state47,48. Given the 
requirement for nuclear localization in disease-mediated toxicity, we sought to determine if the nuclear export 
of polyQ-expanded AR is disrupted and whether enhancing the nuclear export of polyQ-expanded AR would be 
protective in cell models of SBMA. The experiments presented here represent the first investigation of the role 
of AR nuclear export in SBMA pathogenesis and offer new insights into the effect of a polyQ-expansion on this 
important process.
Results
PolyQ-expanded AR exhibits reduced nuclear export. To compare the nuclear export of polyQ-ex-
panded AR with wildtype AR, we utilized a well-characterized PC12 cell model of SBMA in which rat pheo-
chromocytoma-derived PC12 cells express full-length human AR under the control of a tetracycline-inducible 
promoter17,19,49–55. Using PC12 cells expressing AR10Q (wildtype) or AR112Q (polyQ-expanded), we performed 
a heterokaryon shuttling assay, a technique previously used to measure the nuclear export of wildtype AR32–34. 
Briefly, AR expression was induced in PC12 cells for 24 hrs with doxycycline (DOX). Following DOX washout, the 
cells were treated for 2 hrs with DHT to induce AR nuclear translocation and with cycloheximide to block protein 
synthesis from any remaining AR mRNA. Separately, NIH/3T3 mouse fibroblast cells, which lack AR expression, 
were marked by staining with CellTrackerTM Orange CMTMR Dye, a diffuse cytoplasmic marker that converts 
to a membrane-impermeable form after cell uptake. These two cell populations were then fused, generating het-
erokaryons, i.e., cells containing both PC12 and NIH/3T3 nuclei within a shared cytoplasm. Heterokaryons were 
then treated with DHT and cycloheximide for an additional 4 hrs to allow nucleocytoplasmic transport to occur 
between the PC12 (donor) and NIH/3T3 (acceptor) nuclei. While some soluble AR oligomeric species were 
detected by SDS-agarose gel electrophoresis (SDS-AGE) within this timeframe (Fig. S1), intranuclear inclusions 
of AR112Q were not observed. Moreover, the nuclear import of AR10Q and AR112Q was previously shown to 
occur with comparable kinetics19. Following immunohistochemistry, we analyzed heterokaryons by quantifying 
the amount of AR that translocated to the NIH/3T3 nucleus and the amount of AR that remained in the PC12 
nucleus. This analysis revealed that, while AR10Q was evenly distributed between the PC12 and NIH/3T3 nuclei, 
AR112Q was retained to a greater extent within the PC12 nuclei, indicating deficient nuclear export of polyQ-ex-
panded AR (Fig. 1A,B).
To further validate the finding that reduced nuclear export of polyQ-expanded AR occurred prior to intra-
nuclear inclusion formation, we assessed AR nuclear export in a second cell model of SBMA. In isogenic, 
Flp-In HEK293 cells inducibly expressing full-length human AR10Q or AR111Q under the control of a 
tetracycline-inducible promoter, the heterokaryon shuttling assay revealed that AR111Q was retained in the 
HEK293 nucleus of analyzed heterokaryons, while AR10Q was evenly distributed between the HEK293 and 
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NIH/3T3 nuclei (Fig. 1C,D). As in PC12 cells, soluble AR aggregation species were detected in HEK293 cells 
expressing polyQ-expanded AR (Fig. S1); however, intranuclear inclusions of AR111Q were not observed 
until two weeks of treatment with DHT (data not shown). These results demonstrate that the nuclear export of 
polyQ-expanded AR is impaired and that this impairment is not caused by the accumulation of mutant AR into 
insoluble intranuclear inclusions.
The addition of an exogenous NES reduces the aggregation and hormone-induced toxicity of 
polyQ-expanded AR. Having established that polyQ-expanded AR exhibits impaired nuclear export, we 
next wanted to determine if this aspect of AR metabolism plays a role in the aggregation and toxicity of mutant 
AR. Previous studies in several cell and animal models of SBMA have highlighted the requirement of AR nuclear 
localization for disease17,18,46. Thus, we hypothesized that increasing the nuclear export of polyQ-expanded 
AR would be protective in SBMA models. To test this hypothesis, we cloned the previously described NES of 
cAMP-dependent protein kinase inhibitor alpha (MLALKLAGLDI)56 to the N-terminus of the AR and gener-
ated a new, stably transfected clonal PC12 cell line expressing NES-AR108Q. As shown in Fig. 2, NES-AR108Q 
Figure 1. PolyQ-expanded AR exhibits reduced nuclear export. (A,C) Immunofluorescence images of 
heterokaryons formed by fusing PC12 (A) or HEK293 (C) cells, inducibly expressing wildtype or polyQ-
expanded AR, with AR-negative NIH/3T3 cells and treated with 10 nM DHT for 4 hrs post-fusion. NIH/3T3 
nuclei were identified by the presence of bright, condensed chromatin upon Hoechst staining (indicated by 
white arrows). Heterokaryons were verified as two nuclei surrounded by CellTrackerTM Orange CMTMR dye 
with AR in at least one nucleus. (B,D) Quantification of images from (A,C) was performed by measuring the 
fluorescence intensity of AR in the acceptor (NIH/3T3) nucleus relative to the donor (PC12/HEK293) nucleus 
in each heterokaryon. 20–30 heterokaryons were analyzed per condition. Statistical significance was determined 
by Student’s t-test. ***p < 0.001. Experiment (A,B) was repeated five times. Experiment (C,D) was repeated 
three times. Error bars = SD. Scale bars represent 10 μm.
www.nature.com/scientificreports/
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displayed increased distribution to the cytoplasm of PC12 cells in the presence of hormone, compared with equiv-
alently expressed AR112Q (Figs 2A,B, S2A, quantified in Fig. S2B). In the absence of hormone, the localization of 
mutant AR was unaffected by the exogenous NES (Fig. S2A).
Upon treatment with hormone, PC12 cells expressing polyQ-expanded AR form intranuclear inclusions 
that resemble the AR inclusion bodies observed in SBMA patient tissues, in that they consist of proteolyzed 
N-terminal fragments of AR47–49,55. The addition of the exogenous NES reduced the frequency of cells containing 
intranuclear inclusions (Fig. 2B,C). AR aggregation species can be further evaluated by SDS-AGE, an established 
method for resolving large aggregates of polyQ proteins by agarose gel electrophoresis57–59. We have previously 
identified two distinct populations of AR112Q aggregation species by SDS-AGE, slow-migrating aggregates that 
contain full-length AR and are SDS-soluble, and fast-migrating aggregates that contain both full-length AR and 
N-terminal AR fragments, are largely SDS-insoluble, and temporally correlate with intranuclear inclusions54,55. 
Additionally, slow-migrating aggregation species are detected by the 3B5H10 monoclonal antibody, which rec-
ognizes expanded polyQ tracts in low-molecular weight oligomers, but not in higher molecular weight inclusion 
bodies60. The 3B5H10 antibody also recognizes monomeric mutant AR60 and, consistent with this finding, detects 
both cytoplasmic and nuclear NES-AR108Q (Fig. S2C). Increasing AR nuclear export reduced the formation of 
both slow- and fast-migrating aggregation species over time (Fig. 2F). Moreover, NES-AR108Q formed fewer 
3B5H10-immunoreactive oligomers (Fig. 2E). These data suggest that aberrant nuclear retention of AR112Q 
contributes to its aggregation in PC12 cells.
AR expression in PC12 cells also causes polyQ length- and hormone-dependent cell death17, allowing us 
to assess the toxicity of NES-AR108Q in this cell model. We observed that enhancing the nuclear export of 
polyQ-expanded AR eliminated DHT-induced cell death (Fig. 2D). Altogether, these results demonstrate that 
increasing the nuclear export of polyQ-expanded AR has a protective effect on phenotypes relevant to SBMA 
pathogenesis, such as AR aggregation and hormone-induced toxicity, and support the hypothesis that deficient 
nuclear export of polyQ-expanded AR contributes to disease.
Enhancing AR nuclear export promotes its proteasomal degradation. In order to understand the 
mechanism by which increasing the nuclear export of polyQ-expanded AR reduces its aggregation and blocks 
hormone-induced toxicity, we assessed the stability of NES-AR108Q following DHT treatment. Degradation of 
wildtype AR by the ubiquitin-proteasome system in the cytoplasm has been widely reported22–26, while retaining 
polyQ-expanded AR in the cytoplasm by mutating its nuclear localization signal (NLS) leads to autophagic AR 
degradation17. Thus, we hypothesized that targeting mutant AR to the cytoplasm with an exogenous NES could 
increase its degradation by one or both of these pathways. As shown in Fig. 3A–D, the DHT-dependent stabiliza-
tion of polyQ-expanded AR protein was substantially reduced by addition of the exogenous NES. Furthermore, 
the half-life of NES-AR108Q was significantly shorter than that of AR112Q, providing additional evidence that 
enhancing AR nuclear export destabilizes the mutant protein (Figs 3F, S3).
To determine whether the reduction in AR stability was due to increased degradation of NES-AR108Q by 
the proteasome and/or by autophagy, we assessed the ability of DHT to stabilize NES-AR108Q when each of 
these pathways was inhibited. Inhibiting the proteasome with MG132 completely restored NES-AR108Q 
to a level equivalent to AR112Q upon MG132 treatment (Figs 3A,B, S4A), while inhibiting autophagy with 
3-methyladenine (3-MA) had little effect on NES-AR 108Q levels (Figs 3C,D, S4B), indicating that the observed 
decrease in NES-AR108Q stability was a result of its proteasomal degradation. Moreover, in response to proteas-
omal inhibition, we observed an accumulation of NES-AR108Q in the cytoplasm (Fig. 3E, quantification shown 
in Fig. S4C). The observed cytoplasmic deposits of NES-AR108Q (and to a lesser extent of AR112Q) colocalized 
with known markers of aggresomes61–63 – aggregates of misfolded proteins that form when the capacity of the 
proteasome to degrade these proteins is exceeded (such as when the proteasome is inhibited)64 (Fig. S5A,B). 
3B5H10-immunoreactive species were also found within aggresomes (Fig. S5C), suggesting that the reduced 
number of NES-AR108Q aggregation species detectable by this antibody on SDS-AGE (Fig. 2E) is the result of 
enhanced proteasomal degradation of NES-AR108Q in the cytoplasm. Notably, inhibition of autophagy with 
3-MA did not lead to the formation of AR-containing aggresomes (Fig. S5D,E). Taken together, these data indi-
cate that targeting polyQ-expanded AR to the cytoplasm reduces its aggregation and ligand-induced toxicity by 
enhancing its proteasomal degradation.
Reduced serine 650 phosphorylation contributes to the impaired nuclear export of polyQ- 
expanded AR. The nuclear export of wildtype AR was previously shown to be regulated by phosphorylation 
of serine 65034, a residue within the hinge region of the AR. Having found that polyQ-AR is deficient in its nuclear 
export by the heterokaryon shuttling assay, we hypothesized that changes in the phosphorylation state of S650 in 
polyQ-expanded AR could play a role in its impaired nuclear export. Analysis of AR phosphorylation at Serine 
650 (pS650) revealed that polyQ-expanded AR exhibits markedly reduced phosphorylation at S650 compared to 
wildtype AR (Fig. 4A,B). This biochemical analysis was independently confirmed by Proximity Ligation Assay 
(PLA), a technique that can be used to detect, not only interacting proteins, but protein modifications as well. 
Using primary antibodies to detect both total AR and AR pS650, the PLA analysis confirmed our biochemical 
analysis, revealing that polyQ-expanded AR displays reduced phosphorylation at S650 (Fig. 4C,D).
Having established that pS650 is reduced in polyQ-expanded AR, we sought to validate that pS650 regulates 
nuclear export in PC12 cells, as has been reported in COS-7 cells34. New, stably-transfected clonal PC12 cell lines 
expressing wildtype and polyQ-expanded AR with either phospho-null (S650A) or phospho-mimic (S650D) 
mutations were established and DOX doses determined to achieve equivalent AR protein levels in the absence 
of DHT (Fig. 5A). Using the previously described heterokaryon shuttling assay, we assessed the effect of these 
mutations on AR nuclear export. We observed that mutation of S650 to prevent its phosphorylation (S650A) 
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further impaired the nuclear export of polyQ-expanded AR (Fig. 5C,D), suggesting that reduced pS650 may con-
tribute to its nuclear export deficiency. An effect of S650A on the nuclear export of wildtype AR was not observed 
(Fig. S6A,B).
Figure 2. The addition of an exogenous NES reduces the aggregation and hormone-induced toxicity of polyQ-
expanded AR. (A) Western analysis of PC12 cells, expressing AR112Q or NES-AR108Q, treated with DOX 
for 24 hrs, confirmed equivalent expression AR112Q and NES-AR108Q. (B) Immunofluorescence images 
of PC12 cells expressing AR112Q or NES-AR108Q following 72 hrs treatment with 10 nM DHT. Scale bars 
represent 10 μm. (C) Percentage of PC12 cells expressing AR112Q or NES-AR108Q with nuclear inclusions 
following 72 hrs treatment with 10 nM DHT. 300–350 cells were counted in triplicate per condition. Statistical 
significance was determined by Student’s t-test. ***p < 0.001. (D) PC12 cells expressing AR112Q or NES-
AR108Q were treated with 10 nM DHT or ethanol (vehicle) for 12 days. Dead cells were identified via trypan 
blue staining. 200–250 cells were counted in triplicate per condition. Statistical significance was determined 
by one-way ANOVA with post hoc Tukey test. *p < 0.05. (E,F) Western analysis of PC12 cell lysates resolved 
by SDS-agarose gel electrophoresis following treatment with 10 nM DHT for the indicated times. At each time 
point, NES-AR108Q formed fewer aggregation species than AR112Q as detected by 3B5H10 (E) and AR (F) 
antibodies. Note that the signal in the AR10Q and NES-AR10Q lanes represents a monomeric form of AR10Q. 
Experiments were repeated three times. Error bars = SD.
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Figure 3. Proteasome-mediated degradation of NES-AR reduces its stabilization by hormone and decreases its 
half-life. (A) PC12 cells expressing AR112Q or NES-AR108Q were treated with DOX for 24 hrs. Following DOX 
washout, cells were treated for an additional 24 hrs with 10 nM DHT or ethanol (vehicle) and 20 μM MG132 
or DMSO (vehicle) and analyzed by Western blot. (B) Quantification of (A), comparing the protein levels of 
AR112Q with NES-AR108Q for each condition. Statistical significance for each condition was determined by 
Student’s t-test. **p < 0.01. (C) PC12 cells expressing AR112Q or NES-AR108Q were treated with DOX for 
24 hrs. Following DOX washout, cells were treated for an additional 24 hrs with 10 nM DHT or ethanol (vehicle) 
and 5 mM 3-MA or H2O (vehicle) and analyzed by Western blot. (D) Quantification of (C), comparing the 
protein levels of AR112Q with NES-AR108Q for each condition. Statistical significance for each condition was 
determined by Student’s t-test. *p < 0.05, **p < 0.01. (E) Immunofluorescence images of PC12 cells expressing 
AR112Q or NES-AR108Q treated for 24 hrs with 10 nM DHT and 20 μM MG132 or DMSO (vehicle). Scale 
bars represent 5 μm. (F) Determination of AR half-life. PC12 cells expressing AR112Q or NES-AR108Q were 
treated with DOX for 24 hrs. Following DOX washout, cells were treated with 10 nM DHT for 2 hrs, then with 
10 nM DHT and 10 μg/mL cycloheximide for the indicated times. Statistical significance at each time point was 
determined by Student’s t-test. *p < 0.05. Experiments were repeated three times. Error bars = SD.
www.nature.com/scientificreports/
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To investigate the role of S650 phosphorylation in AR aggregation, we compared the frequency of intranuclear 
inclusions of AR112Q, AR S650A 109Q, and AR S650D 109Q in PC12 cells. We found that the phospho-null 
mutation, S650A, did not further increase intranuclear inclusion frequency of polyQ-expanded AR, while the 
S650D mutation actually increased AR aggregation relative to AR S650A 109Q (Fig. 5E).
Altogether, these experiments demonstrate that S650 modulates two aspects of AR metabolism relevant to 
SBMA pathogenesis - aggregation and nuclear retention. We found that the phosphorylation of polyQ-expanded 
AR at S650 was reduced, and that blocking S650 phosphorylation exacerbated the nuclear export deficit of 
polyQ-expanded AR. Additionally, we found that the S650D mutation increased AR intranuclear inclusions 
without affecting its nuclear retention. The mechanism by which S650 regulates these processes remains to be 
explored.
Inhibition of GSK-3β does not promote AR nuclear export in PC12 or HEK293 cells. In addi-
tion to the slow, CRM1-independent nuclear export of AR observed after hormone withdrawal, it has been pro-
posed that the AR undergoes rapid, CRM1-dependent nuclear export upon inhibition of GSK-3β29,30,65. GSK-3β 
is known to phosphorylate and negatively regulate the transcriptional activity of the AR as well as other steroid 
hormone receptors, supporting the notion that the effect of GSK-3β inhibition on AR function may be conserved 
across steroid hormone receptors29,30,65–71. Despite evidence that inhibition of GSK-3β causes rapid nuclear export 
of endogenous and exogenous AR in multiple prostate cancer cell lines, as well as confirmation that the GSK-3β 
inhibitors used here had the expected effect of stabilizing β-catenin levels72 (Fig. 6D), GSK-3β inhibition had no 
effect on the subcellular localization of wildtype or mutant AR in PC12 or HEK293 cells (Fig. 6A,B). Moreover, 
GSK-3β inhibition did not affect the aggregation of polyQ-expanded AR in PC12 cells (Fig. 6C). These findings 
suggest that the mechanism by which GSK-3β regulates AR nuclear export in prostate cancer cell lines does not 
reflect a general mechanism for AR nuclear export in other cellular contexts.
Global disruption of nucleocytoplasmic transport is not observed in cell and animal models of 
SBMA. A number of studies have implicated disruptions in nucleocytoplasmic transport in the pathogenesis 
of neurodegenerative diseases such as ALS73–77 and HD78,79. Given that SBMA is both a neuromuscular disease 
Figure 4. PolyQ-expanded AR exhibits reduced phosphorylation at Serine 650. PC12 cells expressing 
AR10Q or AR112Q were treated with 10 nM DHT for 24 hrs. (A) Immunoprecipitation of total AR followed 
by immunoblotting with an antibody specific to AR phosphorylated at S650 (pS650) revealed a substantial 
decrease in polyQ-expanded AR pS650. (B) Triplicate samples from (A) were quantified by measuring relative 
levels of AR pS650 versus total AR. Statistical significance was determined by Student’s t test. **p < 0.01. (C) 
Immunofluorescence images of PC12 cells expressing AR10Q or AR112Q following proximity ligation assay 
using primary antibodies specific for total AR and AR pS650. Scale bars represent 20 μm. (D) Quantification of 
the number of PC12 cells from C with 0, 1–10, 11–20, or >20 PLA puncta per cell. 155 cells were counted per 
condition. ***p < 0.001 as determined by Kolmogorov-Smirnov test. Experiments were repeated three times. 
Error bars = SD.
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(like ALS) as well as a polyQ repeat disorder (like HD), we sought to investigate whether cell and animal models 
of SBMA display evidence of global disruption in nucleocytoplasmic transport, and whether this could provide a 
mechanism for the impaired nuclear export of polyQ-expanded AR.
Figure 5. Reduced serine 650 phosphorylation contributes to the impaired nuclear export of polyQ-expanded 
AR. (A,B) Western analysis confirmed equivalent expression of AR112Q, AR S650A 109Q, and AR S650D 
109Q in clonal PC12 cell lines following 24 hrs of treatment with DOX. (C) Heterokaryon analysis revealed that 
AR S650A 109Q is more highly retained in the donor (PC12) nucleus than the acceptor (NIH/3T3) nucleus 
(indicated by white arrows). Scale bars represent 10 μm. (D) Quantification of the fluorescence intensity of AR 
in the acceptor nucleus relative to the donor nucleus in each heterokaryon. 20–25 heterokaryons were analyzed 
per condition. Statistical significance was determined by one-way ANOVA with post hoc Tukey test. **p < 0.01, 
***p < 0.001. (E) Percentage of PC12 cells with nuclear inclusions following 48 hrs treatment with 10 nM DHT. 
300–350 cells were counted in triplicate per condition. Statistical significance was determined by one-way 
ANOVA with post hoc Tukey test. *p < 0.05. Experiments were repeated three times. Error bars = SD.
www.nature.com/scientificreports/
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To determine if nucleocytoplasmic transport is broadly disrupted in cells expressing mutant AR, we tran-
siently transfected PC12 cells with tdTomato tagged with both a classical NLS and NES, which undergoes 
Ran-mediated nuclear import and export (a kind gift from J. Rothstein). Mislocalization of NLS-tdTomato-NES 
has been observed in primary cortical neurons expressing mutant huntingtin or TDP-4377,78, and deficient nuclear 
translocation of this protein was reported in neurons from C9orf72 ALS patient-derived induced pluripotent 
stem cells (iPSCs)74. In PC12 cells, expression of polyQ-expanded AR did not affect the nuclear/cytoplasmic 
distribution of NLS-tdTomato-NES (Fig. 7A,B). This suggests that Ran-mediated nuclear transport is not dis-
rupted in PC12 cells expressing mutant AR. However, to further investigate this possibility, we assessed, using 
immunocytochemistry, the localization of specific nucleo/cytoplasmic transport proteins that are disrupted in 
cell and animal models of ALS and HD. Specifically, we examined AR112Q-expressing HEK293 cells and PC12 
cells, as well as transgenic PrP-AR112Q primary motor neurons and spinal cord tissue from 17 month-old trans-
genic PrP-AR112Q mice for alterations in the localization of RanGAP1, a GTPase-activating protein normally 
located on the cytoplasmic filaments of the nuclear pore complex. RanGAP1 plays a key role in maintaining the 
Figure 6. Inhibition of GSK-3β does not promote AR nuclear export in PC12 or HEK293 cells. 
Immunofluorescence images of PC12 (A) and HEK293 (B) cells expressing AR10Q treated for 30 min with 
10 nM DHT then 4 hrs with 10 nM DHT plus GSK-3 inhibitor IV, GSK-3β inhibitor VI, GSK-3 inhibitor XIII, 
or DMSO (vehicle) at the indicated doses. Scale bars represent 10 μm. (C) Percentage of PC12 cells with nuclear 
inclusions following 24 hrs treatment with 10 nM DHT then 24 hrs with 10 nM DHT plus GSK-3β inhibitors or 
DMSO (vehicle) at the indicated doses. 300–350 cells were counted in triplicate per condition. (D) Quantitative 
analysis of GSK-3β inhibitor efficacy on the stabilization of β-catenin, as previously reported72. Western analysis 
of HEK293 cells expressing AR10Q treated with GSK-3 inhibitor IV, GSK-3β inhibitor VI, or DMSO (vehicle) 
for 48 hrs or with GSK-3 inhibitor XIII for 24 hrs (shortened treatment due to toxicity of the compound). 
Western blot shown in Fig. S7. Statistical significance was determined by pairwise comparison of each treatment 
with the control by one-tailed Student’s t test. *p < 0.05. Experiments (A), (B) and (C) were repeated three 
times. Error bars = SD.
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Figure 7. Global disruption of nucleocytoplasmic transport is not observed in cell and animal models of 
SBMA. (A) Immunofluorescence images of PC12 cells expressing AR10Q or AR112Q transiently transfected 
with NLS-tdTomato-NES and treated with 10 nM DHT for 48 hrs. (B) Quantification of (A) was performed by 
measuring the fluorescence intensity of NLS-tdTomato-NES in the nucleus versus the cytoplasm. 80–90 cells 
were analyzed per condition. (C) Ran staining in PC12 cells expressing AR10Q or AR112Q treated for 48 hrs 
with 10 nM DHT+/− 15 min with 400 μM H2O2. Short treatment of cells with H2O2 has been previously shown 
to disrupt the Ran gradient96. (D) Quantification of (C) was performed by measuring the fluorescence intensity 
of Ran in the nucleus versus the cytoplasm. 100 cells were analyzed per condition. Statistical significance was 
determined by one-way ANOVA with post hoc Tukey test. (E) RanGAP1 staining in PC12 cells expressing 
wildtype and polyQ-expanded AR treated with 10 nM DHT for 48 hrs. (F) RanGAP1 staining in primary motor 
neurons from AR112Q transgenic mice treated with DHT for 7 days. Motor neurons were identified by staining 
for neurofilament heavy chain by the SMI32 antibody and by morphology. (G) RanGAP1 staining in motor 
neurons from spinal cord sections of 17 month-old AR112Q transgenic male mice. Note that the merged images 
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nucleo/cytoplasmic gradient of Ran-GTP/GDP that drives active nuclear transport, and mislocalization of this 
protein occurs in numerous cell and animal models of ALS and HD, as well as in C9orf72 and HD patient brain 
tissue74,76–79. In cell and animal models of SBMA, however, we found no evidence of mislocalization of RanGAP1 
or colocalization of RanGAP1 with AR intranuclear inclusions (Figs 7E–G and S2A).
Additionally, we found no disruptions in the Ran gradient in polyQ-expanded AR-expressing HEK293 or 
PC12 cells, further indicating that expression of polyQ-expanded AR does not disrupt Ran-mediated nucleo/
cytoplasmic transport (Figs 7C,D and S2B). Finally, we examined the integrity of the nuclear membrane in PC12 
cells by Lamin B staining and found no evidence of the structural abnormalities that have been observed in mod-
els of ALS and HD73,77,79 (Fig. 7H). Despite sharing common pathological features with these diseases, none of the 
SBMA models examined in this study displayed mislocalization of RanGAP1, disruptions in the Ran gradient, or 
altered nuclear membrane structure. Furthermore, none of these proteins were colocalized with AR intranuclear 
inclusion bodies, despite colocalizing with aggregates of mutant HD, poly(GA), and G4C2 mRNA. Thus, these 
experiments support a hypothesis in which an AR-specific process, rather than a global transport mechanism, 
leads to impaired nuclear export of polyQ-expanded AR.
PolyQ-expanded AR exhibits reduced intranuclear mobility. Previous studies have demonstrated 
that polyQ-expansion can decrease the intranuclear mobility of the protein within which it resides44,80. In order 
to determine if reduced intranuclear mobility of polyQ-expanded AR correlates with its increased nuclear 
retention, we performed fluorescence recovery after photobleaching (FRAP) analysis of cells stably expressing 
AR10Q-Dendra2 or AR109Q-Dendra2. In the absence of stimulation by UV light, proteins tagged with Dendra2 
fluoresce in the green spectrum, allowing for visualization of live cells. This FRAP analysis revealed a modest, but 
statistically significant, decrease in the absolute fluorescence recovery rate of AR109Q-Dendra2 compared with 
AR10Q-Dendra2 over time. Additionally, we found a reduction in the maximum fluorescence recovery achieved 
by AR109Q-Dendra2 post-photobleaching (Fig. 8). It is possible that a slight disruption of intranuclear mobility 
could, along with other factors, contribute to the increased nuclear retention of mutant AR.
Discussion
It has been widely reported that the ligand-dependent nuclear accumulation of mutant AR is required for SBMA 
pathogenesis17,18,46. This mechanistic insight into the toxicity of polyQ-expanded AR ultimately led to clinical 
studies that tested the effect of the androgen suppressors leuprorelin acetate and dutasteride on disease progres-
sion in SBMA patients81–83. Despite recent evidence that long-term treatment with leuprorelin acetate modestly 
slows disease progression84, overall the protective effects of androgen suppressors observed in SBMA animal 
models have not had a substantial impact on disease progression in symptomatic patients. The lack of an effec-
tive treatment for SBMA underscores the need for a better mechanistic understanding of aspects of mutant AR 
metabolism that can be targeted to ameliorate its toxic effects. To this end, the goal of this study was to determine 
if nuclear export, a poorly understood step in the metabolism of AR, plays a role in SBMA pathogenesis and 
whether reducing nuclear AR by enhancing its export can reduce its aggregation and toxicity.
The results of our study demonstrate (1) that the nuclear export of polyQ-expanded AR is impaired, (2) that 
enhancing the nuclear export of polyQ-expanded AR with an exogenous NES decreases its aggregation and tox-
icity by promoting its proteasomal degradation, (3) that polyQ-expanded AR exhibits reduced phosphorylation at 
S650 and that blocking S650 phosphorylation further exacerbates its nuclear export deficiency, and (4) that global 
disruption of nucleo/cytoplasmic transport is not a common feature of SBMA models.
Deficient nuclear export of mutant AR may contribute to its toxicity, as persistence in the nucleus could lead to 
aberrant protein-protein interactions, thereby disrupting normal cellular processes. Indeed, lack of nuclear export 
of polyQ-expanded ataxin-145 correlates with altered protein-protein interactions that contribute to its toxicity by 
both gain-of-function and loss-of-function mechanisms85. An important question for future studies is whether 
AR nuclear export becomes acutely impaired at a polyQ tract length of 38, the threshold for fully penetrant dis-
ease in SBMA patients1. It also remains to be determined if longer polyQ tract lengths correlate with increasing 
impairment of AR nuclear export.
In order to understand why the nuclear export of mutant AR is impaired, we turned to previously published 
insights into the mechanism by which wildtype AR undergoes nuclear export. This led to an investigation of the 
status of S650 phosphorylation of polyQ-expanded AR, as phosphorylation at this residue had been shown to reg-
ulate the nuclear export and nuclear accumulation of wildtype AR34,35. Intriguingly, polyQ-expanded AR exhibits 
substantially reduced pS650 compared with wildtype AR; moreover, genetic mutation to prevent phosphorylation 
of S650 further disrupted the nuclear export of polyQ-expanded AR. These results suggest that the reduced phos-
phorylation of S650 in polyQ-expanded AR may contribute to its deficient nuclear export.
Phosphorylation of the AR is known to regulate numerous aspects of AR function by modulating its interac-
tions with coactivators86. Specifically, expression of the AR coactivator SNURF (small nuclear ring finger protein/
ring finger protein 4) has been shown to slow AR nuclear export and increase AR association with the nuclear 
matrix28. AR phosphorylation at S650 may function similarly, facilitating nuclear export by altering the interac-
tions between AR and its binding partners, perhaps including exportins. Furthermore, changes in the AR inter-
actome that occur upon S650 phosphorylation may also contribute to the process of AR aggregation.
from (F) and (G) include Hoechst staining. (H) Lamin B staining in PC12 cells expressing AR10Q and AR112Q 
treated with 10 nM DHT for 48 hrs. ***p < 0.001. Experiments were repeated three times. Error bars = SD. 
Scale bars represent 10 μm.
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While reduced pS650 represents one mechanism by which the nuclear export of polyQ-expanded AR is 
impaired, the regulation of AR nuclear export likely depends on other signals that remain to be identified. Our 
data indicate that phosphorylation of S650 is not absolutely necessary for AR nuclear export in PC12 cells (as 
AR S650A 109Q still undergoes nuclear export), nor is a phospho-mimic S650D mutation sufficient to rescue 
the impaired nuclear export of polyQ-expanded AR. Nevertheless, elucidating the precise mechanism by which 
pS650 regulates AR nuclear export will be important for developing a better understanding of this process.
The relationship between the role of S650 in regulating AR nuclear export and its regulation of other aspects 
of AR metabolism could offer new insights into how these pathways converge in SBMA. In the present study, we 
found that the S650D mutation increased the frequency of cells with intranuclear inclusions of polyQ-expanded 
AR, demonstrating a role for this residue in AR aggregation. A pressing question is whether facilitation of the 
slow, CRM1-independent nuclear export mechanism for AR actually contributes to its misfolding and aggre-
gation, as suggested by this observation; resolving this question will be the subject of future investigation. 
Additionally, in vitro studies offer evidence for the role of S650 on AR transcriptional activity, finding that a 
phospho-null S650A mutation decreases AR transcriptional activity to varying degrees34,87–89. In humans, an 
S650G mutation has been associated with partial androgen insensitivity syndrome89,90, and alterations in AR 
phosphorylation at S650 have been reported in breast cancer tumors91. Taken together, S650 appears to regulate 
several AR functions relevant to SBMA, making it an intriguing subject for further study.
Another previously reported mechanism of AR nuclear export that we examined in our cell models is the 
CRM1-dependent nuclear export of AR that occurs in several prostate cancer cell lines upon inhibition of 
GSK-3β29,30,65. We were particularly intrigued by the possibility of pharmacologically directing AR export through 
CRM1, as this would mirror the mechanism by which the exogenous NES tag we utilized in our experiments 
directs nuclear export56. In our cell models, however, GSK-3β inhibition had no effect on the subcellular local-
ization of AR. This result, along with our finding that S650 phosphorylation did not affect wildtype AR nuclear 
export in PC12 cells, suggests that previously reported mechanisms of AR export may not be strong regulators of 
polyQ-expanded AR nuclear export. This highlights the need for further investigation into the molecular mech-
anisms underlying the deficient nuclear export of polyQ-expanded AR.
Despite a growing body of evidence that cell-wide disruption of nucleo/cytoplasmic transport is a common 
pathological hallmark of ALS, HD, and other neurodegenerative disorders, we found no evidence for such dis-
ruptions in the SBMA models examined in this study. While we cannot rule out the possibility that nucleo/cyto-
plasmic transport and/or nuclear membrane structure is perturbed in SBMA patient tissue, in the SBMA models 
investigated here, which display numerous aspects of AR aggregation and toxicity characteristic of the disease, 
no global disruption was observed. This finding indicates that, in these models, a general disruption of nucleo/
cytoplasmic transport is not present, and thus not responsible for AR nuclear retention and toxicity. Notably, even 
severely symptomatic transgenic PrP-AR112Q mice exhibit no mislocalization of RanGap1, suggesting that the 
toxicity caused by expression of polyQ-expanded AR is not mediated by defects in nuclear trafficking. Indeed, 
our observation that nucleo/cytoplasmic transport is not disrupted in SBMA models agrees with a recent study 
in which aggregation-prone artificial β-sheet proteins targeted to the cytoplasm, but not to the nucleus, interfered 
with nucleo/cytoplasmic transport machinery of transfected HEK293T cells92. While cytoplasmic AR aggregates 
Figure 8. PolyQ-expanded AR exhibits reduced intranuclear mobility. (A) Averaged absolute FRAP curves of 
PC12 cells expressing AR10Q-Dendra2 or AR109Q-Dendra2 treated with 10 nM DHT for 24 hrs. 22 cells were 
analyzed per condition. Statistical significance was determined by two-way ANOVA. *p < 0.05. (B) Average 
maximum fluorescence recovery achieved by AR10Q-Dendra2 and AR109Q-Dendra2 post-photobleaching. 
Statistical significance was determined by one-tailed Student’s t-test. *p < 0.05. Experiment was repeated three 
times. Error bars = SD.
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have been reported in SBMA patient tissue (particularly in sensory neurons of dorsal root ganglia)93,94, nuclear 
aggregates are more frequently observed and are considered to be a hallmark of disease pathology. Our data sup-
port the theory that nuclear aggregates do not disrupt nucleo/cytoplasmic transport machinery, highlighting an 
important difference between the pathology of SBMA and related neurodegenerative disorders.
This study offers the first evidence that the nuclear export of polyQ-expanded AR is impaired, highlighting a 
novel aspect of AR metabolism that may contribute to the pathogenesis of SBMA. Furthermore, our data support 
a model in which the mutant AR is rapidly degraded by the proteasome once exported from the nucleus, thereby 
decreasing its stability, aggregation, and toxicity. Although additional work will be required to fully elucidate the 
mechanism underlying deficient nuclear export of polyQ-expanded AR, our results provide a new direction for 
investigations into therapeutic manipulation of the mutant, polyQ-expanded AR in SBMA.
Materials and Methods
Cell Culture and Reagents. PC12 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% heat-inactivated horse serum, 5% heat-inactivated fetal bovine serum, 2mM L-glutamine, 
100 units/mL penicillin/streptomycin, 200 μg/mL hygromycin, and 100 μg/mL G418 Sulfate. HEK293 cells were 
maintained in DMEM supplemented with 10% heat-inactivated fetal bovine serum, 2mM L-glutamine, 100 units/
mL penicillin/streptomycin, 15 μg/mL blasticidin S, and 100 μg/mL hygromycin. NIH/3T3 cells were maintained 
in DMEM supplemented with 10% heat-inactivated fetal bovine serum, 2mM L-glutamine, and 100 units/mL 
penicillin/streptomycin. All cells were maintained at 37 °C, 10% CO2. Experiments were performed utilizing char-
coal-stripped serum. For the analysis of AR degradation, cells were treated with 20 μM MG132 (to inhibit the 
proteasome) or 5 mM 3-MA (to inhibit autophagy) for 24 hrs. Cells were lysed and analyzed by western blot as 
described below.
Heterokaryon Shuttling Assay. The heterokaryon shuttling assay for analysis of AR nuclear export was 
carried out using modifications of the protocol of Black et al., 2001. Stable Tet-On PC12 cells expressing AR10Q 
or AR112Q were treated with 500 ng/mL doxycycline for 24 hrs to induce AR expression. Separately, NIH/3T3 
mouse fibroblast cells were plated in complete media. Prior to fusion, actively growing NIH/3T3 cells were stained 
with 1 μM CellTrackerTM Orange CMTMR Dye in Optimem for 45 min, then incubated for an additional 60 min 
in complete media. Concurrently, PC12 cells were washed of doxycycline and treated for 2 hrs with 10 nM DHT 
(to induce nuclear localization of the AR) and 10 μg/mL cycloheximide (to inhibit protein synthesis).
PC12 cells and stained NIH/3T3 cells were trypsinized, mixed in Optimem at a 1:1 ratio, and then pelleted. 
The cells were fused in suspension with 100 μL 50% PEG-1500 (w/v) added slowly over 2 min. The cell/PEG-1500 
mixture was then diluted with 5 mL Optimem, added slowly during an additional 3 min. The fused cells were pel-
leted and re-plated onto poly-D-lysine coated coverslips in the presence of 10 nM DHT and 10 μg/mL cyclohex-
imide for 4 hrs prior to fixation and immunostaining.
Immunostaining. Immunostaining was carried out as described by Montie et al., 2009 following 20 min 
fixation in 4% paraformaldehyde. Spinal cord tissue was embedded in OCT and cryosectioned (7μm) prior to 
fixation. All animal procedures were performed following the guidelines of the Office of Laboratory Animal 
Welfare and with the approval of the Thomas Jefferson University Institutional Animal Care and Use Committee.
Antibodies used include: AR (H280, Santa Cruz Biotechnology), AR (AR-318-CE, Leica Biosystems), AR 
pS650 (ab47563, Abcam), RanGAP1 (H180, Santa Cruz Biotechnology), Ran (610340, BD Transduction 
Laboratories), Lamin B1 (ab16048, Abcam), HDAC6 (D21B10, Cell Signaling Technology), HSP70 (SMC-100, 
StressMarq), neurofilament-heavy chain (SMI32; 801701 Sternberger Monoclonals), and 3B5H10 (a kind gift 
from Dr. Steve Finkbeiner, Gladstone Institute of Neurological Disease and UCSF). Immunostained cells were 
visualized using a Leica DMR Fluorescence microscope (Leica Microsystems GmbH, Wetzlar, Germany) and 
imaged using iVision Mac® or ProgRes® software.
In PC12 cells, the percentage of inclusions was determined by counting at least 300 cells in triplicate wells. 
Experiments were repeated at least three times.
Western blot analysis. Protein extracts were prepared by lysing cells in Triton-DOC lysis buffer (1% 
sodium deoxycholate, 0.5% Triton X-100 in PBS with protease inhibitors). All lysates were sonicated at least three 
times for 10 s using a Branson cup sonifier. Protein concentration was determined by DC protein assay (Bio-Rad). 
Lysates were electrophoresed by SDS-PAGE and transferred to 0.45 μm PVDF membrane (Immobilon-P). Blots 
were incubated with primary antibodies diluted in 5% nonfat milk in TBST (TRIS-buffered saline, 0.1% Tween-
20) for 60 min at room temperature or overnight at 4 °C and with HRP-conjugated secondary antibodies (mouse: 
AP308P, rabbit: AP307B; Millipore) for 60 min at room temperature. Detection was performed using ECL sub-
strate (Thermo Fisher) with analysis on a ChemiDoc MP (Bio-Rad).
Antibodies used include: AR (H280, Santa Cruz Biotechnology), AR pS650 (ab47563, Abcam), α-tubulin 
(21445, Cell Signaling Technology), β-catenin (8480 T, Cell Signaling Technology), Lamin B1 (ab16048, Abcam), 
p62 (ab56416, Abcam), and GAPDH (10R-G109A, Fitzgerald).
PC12 Cell Toxicity Assay. Stable Tet-On PC12 cells expressing AR112Q or NES-AR108Q were treated with 
500 ng/mL doxycycline (to express equivalent levels of AR) in the presence and absence of 10 nM DHT for 12 
days. The percentage of dead cells was determined by counting the percentage of Trypan blue-positive cells; sam-
ples were blinded prior to counting. Three independent experiments were performed in triplicate with at least two 
hundred cells counted per condition.
SDS-agarose gel electrophoresis (SDS-AGE). PC12 cells were lysed in Triton-DOC lysis buffer (1% 
sodium deoxycholate, 0.5% Triton X-100 in PBS with protease inhibitors) and diluted 1:1 in non-reducing 
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Laemmli sample buffer. Samples were boiled for 5 minutes and electrophoresed through a 1% agarose gel con-
taining 0.1% SDS in 375 mM Tris-HCL, pH 8.8, for approximately 18 hrs at 4 °C. Lysates were then transferred 
to a 0.45 μm PVDF membrane at 200 mA for 3 hrs using a semi-dry transfer apparatus (Owl HEP Semidry 
Electroblotting Systems, Thermoscientific). A 4 kg weight was placed on top of the transfer apparatus to accom-
modate thinning of the agarose gel during transfer. Western analysis was performed using anti-AR (H280, Santa 
Cruz Biotechnology) or 3B5H10 (a kind gift from Dr. Steve Finkbeiner, Gladstone Institute of Neurological 
Disease and UCSF) antibodies.
Protein Turnover Assay. AR expression was induced with doxycycline in PC12 cell lines expressing 
AR112Q or NES-AR108Q for 24 hrs. Cells were then washed with PBS to remove media containing doxycycline 
and treated with media containing 10 nM DHT for 2 hrs. Subsequently, cells were treated with media containing 
10 nM DHT and 10μg/mL cycloheximide for 10 hrs. Cells were harvested at the given time points after the final 
media replacement and analyzed by Western blot, as described above.
Creation of clonal PC12 cell lines. The NES-AR plasmid was constructed by excision of pCMV NES-AR 
(N-terminal fragment) (a kind gift from Andrew Lieberman, University of Michigan) with SnaBI/EagI and ligation 
into a preexisting pTRE AR112Q plasmid by sequential digests with NheI (blunted with DNA polymerase I, large 
(Klenow) fragment) and EagI. The NES utilized in this study (ATGTTAGCCTTGAAATTAGCAGGATTAGACATC) 
was originally identified in cAMP-dependent protein kinase inhibitor alpha56.
AR-Dendra2 plasmids were constructed by mutation of the AR STOP codon to an AgeI restriction enzyme 
site by PCR, excision of the AR C-terminus from this PCR product by BstBI/AgeI digestion, and ligation into a 
pGWI-Dendra2 plasmid (kind gift of Dr. Steven Finkbeiner, Gladstone Institute of Neurological Disease and 
UCSF). C-terminally tagged AR-Dendra2 was then excised with BstBI/XbaI and ligated into preexisting pTRE 
AR10Q and pTRE AR112Q plasmids.
Mutation of AR Serine 650 to alanine or aspartate was performed by site-directed mutagenesis (QuikChange 
II, Stratagene) of the pTRE AR10Q and pTRE AR112Q plasmids. The AR coding region was then sequenced to 
verify the absence of secondary mutations.
Stable transfection of Tet-On PC12 cells with these AR constructs and a plasmid conferring hygromycin 
resistance (pTK-hygromycin) in a 1:4 molar ratio was then performed using lipofectamine 2000 according to 
the manufacturer’s instructions. Stable transformants were selected with 200 μg/mL hygromycin. Single colonies 
were isolated and screened for AR protein expression by induction with 1 μg/mL doxycycline and western blot-
ting using an anti-AR antibody (H280, Santa Cruz Biotechnology). Genomic DNA was extracted from positive 
clones, and the CAG repeat length was verified by PCR and sequencing analysis. The concentration of doxy-
cycline required to induce equivalent levels of AR protein between cell lines was determined and used for all 
experimentation.
Immunoprecipitation. PC12 cells were pelleted in PBS and lysed in NP-40 buffer (20 mM HEPES-NaOH 
pH 7.9, 100 mM NaCl, 2 mM MgCl2, 0.1% NP-40) supplemented with protease and phosphatase inhibitors. 
Lysates were incubated on ice for 30 min and cleared by centrifugation. Protein concentration was determined 
using a DC protein assay (Bio-Rad) and samples were diluted to 1 mg/mL for the IP reaction with 10μg reserved 
for the input control. 0.5 mg of lysates was incubated with 1μg of AR antibody (BD Biosciences) or mouse IgG, 
crosslinked to Dynabeads M-270 Epoxy (Invitrogen) overnight at 4 °C with rotation. Immunoprecipitated protein 
was washed 3–4 times with lysis buffer and eluted with Laemmle buffer for western analysis.
Proximity Ligation Assay. PC12 cells were plated on poly-D-lysine coated glass coverslips and treated with 
500 ng/mL doxycycline and 10 nM DHT for 24 hrs. Duolink® PLA Fluorescence protocol was performed per 
manufacturer’s instructions (DUO92008, Sigma-Aldrich) with primary antibodies against total AR (AR-318-CE, 
Leica Biosystems) and AR pS650 (ab47563, Abcam). Images were acquired with the same exposure time.
Dissociated Spinal Cord Cultures. Dissociated spinal cord cultures were established as previously 
described17,95. Briefly, spinal cords were dissected from embryonic day 13.5 PrP-AR112Q transgenic mice, dis-
sociated with trypsin, and plated on poly-D-lysine coated coverslips in 24-well plates. Cultures were grown 
in glia-conditioned media containing minimal essential medium, 3% charcoal-stripped horse serum, 35 mM 
NaHCO3, 0.5% dextrose, 1% N3, and 10 nM 2.5 S nerve growth factor for 3 weeks. Cultures were then treated with 
either ethanol or 10μM DHT for 7 days. Motor neurons were identified by the presence of neurofilament-heavy 
chain (SMI32 immunoreactivity) and morphology.
Fluorescence Recovery After Photobleaching. PC12 cells stably expressing AR10Q-Dendra2 or 
AR109Q-Dendra2 were plated on poly-D lysine-coated glass bottom dishes (MatTek Corp). AR expression was 
induced with 500 ng/mL doxycycline and cells were treated with 10 nM DHT for 24 hrs. Prior to imaging, media 
was replaced with Opti-MEM I minus phenol red (Gibco), supplemented with 500 ng/mL doxycycline and 10 nM 
DHT. Live cell imaging was performed on a Nikon A1R microscope with cells maintained at 37 °C and 5% CO2. 
Cells of approximately the same starting intensity were selected for photobleaching in a designated region of 
interest (ROI) within the cell nucleus, excluding the nucleolus. Photobleaching was performed using the 490 nm 
later at 10% power for 4 iterations. Fluorescent recovery within the bleached zone was measured every 0.5 sec 
for 30 sec, using the 490 nm later at 0.7% power. Absolute fluorescent recovery was determined by the percent 
of fluorescent recovery relative to the starting (pre-bleach) fluorescent intensity of the ROI. Maximum recovery 
represents the greatest percent of fluorescent recovery within an ROI independent of time.
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Statistical analysis. For pairwise comparisons, statistical significance was determined by two-tailed 
Student’s t-test unless otherwise noted in figure legends. For multiple comparisons, statistical significance was 
determined by one-way analysis of variance (ANOVA) with post-hoc Tukey test. For comparison of distributions, 
statistical significance was determined by the Kolmogorov-Smirnov test. The significance level (α) was set at 0.05 
for all experiments. Data were compiled and analyzed using Microsoft Excel or Prism 7 (GraphPad).
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